Phase Ib/II trial
Showing 1 - 25 of >10,000
Advanced Solid Tumor Trial in Shanghai (JS015, Toripalimab, Paclitaxel)
Not yet recruiting
- Advanced Solid Tumor
- JS015
- +10 more
-
Shanghai, Shanghai, ChinaShanghai East Hospital
Nov 17, 2023
Advanced Solid Tumors Trial (AK127 in combination with AK112)
Not yet recruiting
- Advanced Solid Tumors
- AK127 in combination with AK112
- (no location specified)
Jul 11, 2023
Sarcoma Trial in Guangzhou (Fluzoparib+ Dalpiciclib)
Recruiting
- Sarcoma
- Fluzoparib+ Dalpiciclib
-
Guangzhou, Guangdong, ChinaCancer Center of Sun-Yat Sen University (CCSYSU)
Jul 11, 2023
Advanced Solid Tumors Trial (SHR-A2009 for injection ; Almonertinib Mesilate Tablets, SHR-A2009 for injection;Adebrelimab
Not yet recruiting
- Advanced Solid Tumors
- SHR-A2009 for injection ; Almonertinib Mesilate Tablets
- SHR-A2009 for injection;Adebrelimab Injection
- (no location specified)
Oct 17, 2023
Relapsed or Refractory Peripheral T-cell Lymphoma (PTCL) Trial (GFH009)
Not yet recruiting
- Relapsed or Refractory Peripheral T-cell Lymphoma (PTCL)
- (no location specified)
Jun 28, 2023
NASH, NAFLD Trial in Hangzhou (GH509, Placebo)
Recruiting
- NASH
- NAFLD
- GH509
- Placebo
-
Hangzhou, Zhejiang, ChinaThe Affiliated Hospital of Hangzhou Normal University
Mar 26, 2023
Advanced Solid Tumor Trial (Adebrelimab, SHR-1802, Carboplatin/Cisplatin)
Not yet recruiting
- Advanced Solid Tumor
- Adebrelimab
- +3 more
- (no location specified)
Mar 20, 2023
Gastric Cancer, Gastroesophageal Junction (GEJ) Cancer Trial (T-Dxd(Trastuzmab deruxtecan), Ramucirumab)
Not yet recruiting
- Gastric Cancer
- Gastroesophageal Junction (GEJ) Cancer
- T-Dxd(Trastuzmab deruxtecan), Ramucirumab
- (no location specified)
Jun 7, 2023
Acute Gout Trial in Wuhan, Linyi, Shanghai (Recombinant Anti-IL-1ß Humanized Monoclonal Antibody Injection 100 mg (phase Ib),
Recruiting
- Acute Gout
- Recombinant Anti-IL-1β Humanized Monoclonal Antibody Injection 100 mg (phase Ib)
- +6 more
-
Wuhan, Hubei, China
- +2 more
Oct 17, 2022
Inhibition of Autophagy Synergizes Anti-tumor Effect Trial in Guangzhou (100mg bid dose of hydroxychloroquine combined with
Recruiting
- Inhibition of Autophagy Synergizes Anti-tumor Effect
- 100mg bid dose of hydroxychloroquine combined with three predefined dose groups of palbociclib
- RP2D dose of 100mg bid of hydroxychloroquine combined with palbociclib was selected for phase II clinical trial.
-
Guangzhou, Guangdong, ChinaSun Yat-Sen Memorial Hospital of Sun Yat-Sen University
Jul 19, 2023
Melanoma Trial in Beijing (IBI363)
Not yet recruiting
- Melanoma
- IBI363
-
Beijing, Beijing, ChinaBeijing Cancer Hospital
Oct 7, 2023
Advanced Liver Cancer Trial in Chengdu (QL1706, QL1604, Bevacizumab)
Recruiting
- Advanced Liver Cancer
- QL1706
- +2 more
-
Chengdu, Sichuan, ChinaWest China Hospital, Sichuan University
Nov 1, 2022
Unresectable Hepatocellular Carcinoma, Pembrolizumab, Lenvatinib Trial in Taipei City (Lenvatinib/Pembrolizumab plus SBRT
Not yet recruiting
- Unresectable Hepatocellular Carcinoma
- +3 more
- Lenvatinib/Pembrolizumab plus SBRT combinations
-
Taipei City, Taiawn, TaiwanNational Taiwan University Hospital
Jan 30, 2023
Esophagogastric Adenocarcinoma Trial (Sacituzumab govitecan)
Not yet recruiting
- Esophagogastric Adenocarcinoma
- Sacituzumab govitecan
- (no location specified)
Nov 9, 2023
Non-hodgkin's Lymphoma Trial in Beijing (GNC-038)
Recruiting
- Non-hodgkin's Lymphoma
-
Beijing, Beijing, ChinaBeijing Cancer Hospital
Jan 12, 2023
Non Small Cell Lung Cancer Trial (HLX208+HLX10)
Not yet recruiting
- Non Small Cell Lung Cancer
- HLX208+HLX10
- (no location specified)
Nov 30, 2022
Acute Lymphoblastic Leukemia Trial in Tianjin (CN201)
Recruiting
- Acute Lymphoblastic Leukemia
-
Tianjin, Tianjin, ChinaInstitute of Hematology & Blood Diseases Hospital
Oct 14, 2022
Serous Ovarian Cancer, Advanced Ovarian Cancer Trial (SC0191, Gemcitabine, Paclitaxel)
Not yet recruiting
- Serous Ovarian Cancer
- Advanced Ovarian Cancer
- SC0191
- +2 more
- (no location specified)
Sep 20, 2023
Hepatocellular Carcinoma Trial in Shanghai (BC3402 injection, Durvalumab injection)
Not yet recruiting
- Hepatocellular Carcinoma
- BC3402 injection
- Durvalumab injection
-
Shanghai, ChinaZhongshan Hospital, Fudan University
Oct 26, 2023
Advanced Malignant Tumors Trial in Shanghai (AK104, AK117, Capecitabine tablets)
Recruiting
- Advanced Malignant Tumors
- AK104
- +8 more
-
Shanghai, ChinaShanghai Renji Hospital
Aug 9, 2022
TNBC Trial in Shanghai (PM8002, nab-paclitaxel)
Recruiting
- TNBC
-
Shanghai, ChinaFudan University Shanghai Cancer Center
Jun 25, 2023
Locally Advanced Biliary Tract Cancer, Metastatic Biliary Tract Cancer Trial in Guangzhou (Camrelizumab and Apatinib Plus GP)
Not yet recruiting
- Locally Advanced Biliary Tract Cancer
- Metastatic Biliary Tract Cancer
- Camrelizumab and Apatinib Plus GP
-
Guangzhou, Guangdong, ChinaCancer center of SunYat-sen University
Feb 15, 2023
High-Risk Localized Soft Tissue Sarcoma Trial in Shanghai (Surufatinib, Sintilimab, Radiotherapy)
Recruiting
- High-Risk Localized Soft Tissue Sarcoma
- Surufatinib
- +2 more
-
Shanghai, Shanghai, ChinaFudan University Shanghai Cancer Center
Apr 20, 2023
Advanced Renal Cell Carcinoma Trial in Beijing (ST-1898 tablets)
Recruiting
- Advanced Renal Cell Carcinoma
- ST-1898 tablets
-
Beijing, Beijing, ChinaPeking University Cancer Hospital & Institute
Nov 6, 2023